Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$28.50
Change (%)0.00 (0.00%)
Volume0
Data as of 09/22/17 4:00 p.m. ET
Refresh quote
Featured Events
Webcast ImageWebcast
Global Blood Therapeutics Inc at the Cantor Fitzgerald Global Healthcare Conference  (Live)
09/26/17 at 1:05 p.m. ET
Global Blood Therapeutics Inc at the Cantor Fitzgerald Global Healthcare Conference
Tuesday, September 26, 2017 1:05 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast
GBT at the 2016 American Society of Hematology (ASH) Annual Meeting (Replay)
12/05/16 at 12:15 p.m. PT
ASH 2016 Poster: Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor
ASH 2016 Poster: The 9-Item Sickle Cell Disease Severity Measure (SCDSM): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor
ASH 2016 Poster: Absorption, Metabolism, and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects
Corporate Presentation
Download Documentation Corporate Presentation (September 2017)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
09/06/17Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference
Healthcare Providers, Patient Advocates, Government Agencies and Industry Will Discuss Critical Issues Facing SCD Community During National Sickle Cell Disease Awareness Month Livestream of Conference Will Be Available Through Collaboration with Sickle Cell Warriors SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will host the Annual Sickle Cell Disease (SCD) Therapeutics Conference, which will take... 
Printer Friendly Version
09/05/17Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD)
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to GBT440 for the treatment of sickle cell disease (SCD). GBT440 is being developed as a potentially disease-modifying therapy for SCD. “The FDA’s Rare Pediatric Disease designation for GBT440, in addition to the previously granted Orphan Drug and Fast Track designati... 
Printer Friendly Version
08/30/17Global Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in September: 12th Annual Wells Fargo Securities Healthcare Conference in Boston on Wednesday, September 6, 2017 at 10:50 a.m. Eastern Time (ET); Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 13, 2017 at 11:40 a.m. ET; and Cantor Fitzgerald Global Healthcar... 
Printer Friendly Version
08/09/17Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City on Wednesday, August 16 at 10:55 a.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section. About Global Blood Therapeutics Global Blood Therapeutics, Inc. is a clinical-stage biopha... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
09/26/17 1:05 p.m. ET
Global Blood Therapeutics Inc at the Cantor Fitzgerald Global Healthcare Conference
LocationNew York, NY
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.